

P22618.P01 UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No. P22618	Total Pages 35	Inventor(s) or Application Identifier: Kouichi SEKIYA, and Akihiro TAKEMIYA
Title: PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF			
ADDRESS TO: Commissioner for Patents Mail Stop Patent Application PO Box 1450 Alexandria, VA 22313-1450			
APPLICATION ELEMENTS	ACCOMPANYING APPLICATION PARTS		
1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing) 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. a. <input type="checkbox"/> Small Entity Statement(s) 3. <input checked="" type="checkbox"/> Specification (preferred arrangement set forth below) [Total Pages <u>35</u>] - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets <u> </u>] 5. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages <u>4</u>] a. <input type="checkbox"/> Newly executed (original or copy) <input type="checkbox"/> Unexecuted b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20 completed) [Note Box 6 below] i. <input checked="" type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. 7. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 8. <input type="checkbox"/> CD-Rom or CD-R in duplicate, large table or Computer Program (Appendix)	9. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper c. <input type="checkbox"/> Statements verifying identity of above copies 10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee) 12. <input type="checkbox"/> English Translation Document (if applicable) 13. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Citations Statement (IDS)/PTO-1449 14. <input type="checkbox"/> Preliminary Amendment 15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 16. <input type="checkbox"/> Figure of Drawing to be published 17. <input checked="" type="checkbox"/> Foreign priority claimed a. <input checked="" type="checkbox"/> Claim of Priority b. <input type="checkbox"/> Certified Copy of Priority Document(s) 18. <input checked="" type="checkbox"/> Assignee: <u>Mitsubishi Chemical Corporation, of Tokyo, Japan</u> 19. <input checked="" type="checkbox"/> Other: <u>Request for Deletion of Inventors Under 37 C.F.R.</u> <u>1.63(d)(2) and Naming of Inventive Pursuant to 37</u> <u>C.F.R. 1.53(B)</u> _____ _____ _____		
20. If a CONTINUING APPLICATION , check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. <u>09/926,477</u> , filed <u>May 9, 2000</u> . Prior application information: Examiner: _____ Group Art Unit: _____			
21. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: This application is a <u> </u> continuation-in-part, <u> </u> continuation, <u> </u> divisional, of Application No. <u> </u> / <u> </u> , filed <u> </u> .			

00746 U.S. PTO
 10/631795
 06/01/03

Address all future correspondence to **Customer No. 7055** at the present address of:

GREENBLUM & BERNSTEIN, P.L.C.
 1950 Roland Clarke Place
 Reston, VA 20191
 (703) 716-1191

8/1/03

Date

Bruce H. Bernstein

Signature 33,094

Bruce H. Bernstein, Reg. No. 29,027
 Typed or Printed Name

P22618.P02

15915 U.S. PTO

FEE TRANSMITTAL

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Concurrently Herewith
First Named Inventor	Kouichi SEKIYA et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	P22618

TOTAL AMOUNT OF PAYMENT (\$750.00)

METHOD OF PAYMENT (check one)

FEE CALCULATION (continued)

1. ☒ The U.S. Patent and Trademark Office is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 19-0089

Deposit Account Name GREENBLUM & BERNSTEIN, P.L.C.

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3))
- ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance, 37 CFR 1.311(b)
- ☐ Applicant Claims Small Entity Status See 37 CFR 1.27.

2. ☒ Payment Enclosed:

☒ Check ☐ Credit Card ☐ Money Order ☐ Other

FEE CALCULATION (fees effective 01/01/03)

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	750.00
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 750.00

2. CLAIMS

Total Claims	Extra	Fee from below	Fee Paid
7	-20=	0 x 18 =	0.00
Independent 3	-3=	0 x 84 =	0.00
Multiple Dependent Claims	0	x 280 =	0.00

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim
1204	84	2204	42	Reissue independent claims over original patent
1205	18	2205	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR	
				Prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for response within 1st month	
1252	410	2252	205	Extension for response within 2nd month	
1253	930	2253	465	Extension for response within 3rd month	
1254	1,450	2254	725	Extension for response within 4th month	
1255	1,970	2255	985	Extension for response within 5th month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive unavoidably abandoned application	
1453	1,300	2453	650	Petition to revive unintentionally abandoned application	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of IDS	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

Other fee (specify) _____

SUBTOTAL (3) (\$) 0.00

*Reduced by Basic Filing Fee paid

SUBMITTED BY

Complete (if applicable)

Typed or Printed Name	Bruce H. Bernstein	Reg. Number	29,027
Signature	<i>Bernstein</i>	Date	8/1/03
	Reg. 42,357	Deposit Account User ID	

P22618.A01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kouichi SEKIYA et al.

Group Art Unit : 1624

Appln. No : Not Yet Assigned

Examiner : Unknown

Filed : Concurrently Herewith

For : PURINE DERIVATIVE DIHYDRATE, DRUGS CONTAINING THE SAME AS THE
ACTIVE INGREDIENT AND INTERMEDIATE IN THE PRODUCTION THEREOF

**REQUEST FOR DELETION OF INVENTORS UNDER 37 C.F.R. 1.63(d)(2)
AND
NAMING OF INVENTIVE ENTITY PURSUANT TO 37 C.F.R. 1.53(B)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.53(b) and 37 C.F.R. 1.63(d)(2), Applicants hereby request
deletion of the following inventor named in parent Application No. 09/926,477, filed May 9,
2000 as PCT/JP00/02952:

Masahiro OHSHIMA.

Accordingly, Kouichi SEKIYA and Akihiro TAKEMIYA are named as inventors of the
present application.

Therefore, the inventors of the presently claimed invention are:


Kouichi SEKIYA, and

Akihiro TAKEMIYA.

P22618.A01

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Kouichi SEKIYA et al.


Bruce H. Bernstein
Reg. No. 29,027

Spec. 33,094

August 1, 2003
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191